| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
Taniborbactam diHCl (VNRX-5133) is a parenteral, potential best-in-class, reversible, specific boronic acid-containing compound that inhibits both serine- and metallo-β-lactamases with IC50s of 8-530 nM. Combined with cefepime, a fourth generation cephalosporin antibiotic, taniborbactam drives antimicrobial activity against gram-negative bacteria that have acquired multi-drug resistance (MDR) via classes A, B, C and D β-lactamase expression. Taniborbactam is the only known β-lactamase inhibitor in advanced clinical development that blocks class B carbapenemases. In 2019, Everest Medicines and licensing partner Venatorx Pharmaceuticals initiated a global Phase 3 clinical trial for patients with complicated urinary tract infections (cUTI).
| ln Vitro |
The half-life of taniborbactam hydrochloride (VNRX-5133 hydrochloride) is 0.5 nM for Klebsiella pneumoniae strains KPC-2, OXA-48, and VIM-4, and 0.5 nM for P. aeruginosa strain VIM-2. The minimum inhibitory concentration (MIC) ranges for cefepime hydrochloride/taniborbactam (10 μg/mL), 0.5 nM, and meropenem/taniborbactam combinations against Escherichia coli and Klebsiella pneumoniae were 16-0.25, respectively. together with 1-0.125 μg/mL[1].
|
|---|---|
| ln Vivo |
In a neutropenic mouse lung infection model, a single dosage of cefepime (32 mg/kg) and tantaborbactam hydrochloride (VNRX-5133 hydrochloride; 16 mg/kg; sc) increased survival. Bacterial population reduction more than 4 log10 and against strains of K. pneumoniae that produce CTX-M-14 [2]. Cefepime (16 mg/kg) and tanibobactam hydrochloride (16 mg/kg; subcutaneous injection; twice daily for 7 days) together produced >2 log10 decrease against CTX-M-15-producing E. coli strains and raised live bacterial counts in the kidneys of an ascending urine infection model [2]. In mice, taniborbactam hydrochloride has a T1/2 of 0.16 hours, a CL of 618 mL/h/kg, and a Vss of 143 mL/kg[2].
|
| References |
| Molecular Formula |
C19H30BCL2N3O5
|
|---|---|
| Molecular Weight |
462.17560338974
|
| Exact Mass |
461.165
|
| CAS # |
2244235-49-0
|
| Related CAS # |
Taniborbactam;1613267-49-4
|
| PubChem CID |
137331954
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
544
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl.Cl.O=C(CC1CCC(CC1)NCCN)N[C@@H]1B(O)OC2C(C(=O)O)=CC=CC=2C1
|
| InChi Key |
CKWIMFZHNCBHIX-DKZBTPFISA-N
|
| InChi Code |
InChI=1S/C19H28BN3O5.2ClH/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)2*1H/t12-,14-,16-/m0../s1
|
| Chemical Name |
(3R)-3-(2-{trans-4-[(2-aminoethyl)amino]cyclohexyl}acetamido)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic
acid dihydrochloride
|
| Synonyms |
Taniborbactam dihydrochloride VNRX-5133 VNRX5133 VNRX 5133
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~432.73 mM)
H2O : ~33.33 mg/mL (~72.11 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 0.5 mg/mL (1.08 mM) (saturation unknown) in 1% DMSO 99% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 7: 50 mg/mL (108.18 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1637 mL | 10.8183 mL | 21.6366 mL | |
| 5 mM | 0.4327 mL | 2.1637 mL | 4.3273 mL | |
| 10 mM | 0.2164 mL | 1.0818 mL | 2.1637 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
